|
Boehringer Ingelheim Presents Phase 3 Data for Tiotropium Across Asthma …
PR Newswire (press release) RIDGEFIELD, Conn., March 1, 2014 /PRNewswire/ — Boehringer Ingelheim today presented data from Phase 3 studies of tiotropium delivered via the Respimat® inhaler in mild, moderate and severe asthma patients at the 2014 American Academy of Allergy, … |
View full post on asthma – Google News